2024
Brivaracetam use in children with epilepsy: A retrospective multicenter study
ŠPILÁROVÁ, Zuzana, Sára SLÁDKOVÁ, A. BELOHLAVKOVA, Katarína ČESKÁ, Petra HANÁKOVÁ et. al.Základní údaje
Originální název
Brivaracetam use in children with epilepsy: A retrospective multicenter study
Autoři
ŠPILÁROVÁ, Zuzana (703 Slovensko, domácí), Sára SLÁDKOVÁ (203 Česká republika, domácí), A. BELOHLAVKOVA (203 Česká republika), Katarína ČESKÁ (703 Slovensko, domácí), Petra HANÁKOVÁ (203 Česká republika, domácí), Ondřej HOŘÁK (203 Česká republika, domácí), A. JAHODOVA (203 Česká republika), Lenka KNEDLÍKOVÁ (203 Česká republika, domácí), Senad KOLÁŘ (203 Česká republika, domácí), M. EBEL (203 Česká republika), M. KUDR (203 Česká republika), Hana OŠLEJŠKOVÁ (203 Česká republika, domácí), Michal RYZÍ (203 Česká republika, domácí), Klára ŠPANĚLOVÁ (203 Česká republika, domácí), K. STERBOVA (203 Česká republika), Anna KOUBOVÁ (203 Česká republika), P. KRSEK (203 Česká republika) a Pavlína DANHOFER (203 Česká republika, garant, domácí)
Vydání
Seizure-European journal of epilepsy, London, W.B. Saunders Ltd. 2024, 1059-1311
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30210 Clinical neurology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.000 v roce 2022
Organizační jednotka
Lékařská fakulta
UT WoS
001321205400001
Klíčová slova anglicky
Brivaracetam; Pediatric epilepsy; Response rate; Retention rate; Overnight switch; Side effects
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 8. 10. 2024 14:03, Mgr. Tereza Miškechová
Anotace
V originále
Purpose: This retrospective multicenter study aimed to assess the efficacy and safety of brivaracetam (BRV) in pediatric epilepsy.
Methods: Our cohort consisted of 93 children (mean age 11.5 +/- 7.5 years) with a wide spectrum of pediatric epilepsy, including epileptic encephalopathy and generalized epilepsy. Of these, 61 (60.4%) were diagnosed with focal epilepsy, 19 (15.8%) with generalized epilepsy, and 16 (15.8%) with combined epilepsy, while 8 patients (7.9%) had an unknown epilepsy type. The cohort included rare epilepsy syndromes: 8 patients with LennoxGastaut syndrome, 3 with Dravet syndrome, and 1 with Rasmussen syndrome. Patients had a history of various antiseizure medications (ASMs) (6.42 +/- 3.15), and on average, were being treated with more than two (2.57 +/- 1.16) drugs at the time of BRV deployment. Results: Retention rates were high, with 80.6% of patients adhering to treatment at 3 months, 66.7% at 6 months, and 45.2% at 12 months. In 29 patients (30.1%), BRV was added in an overnight switch from levetiracetam (LEV), resulting in a reduction of behavioral adverse effects (AEs) in 5 patients (17.2%). The response rate was 25.8% at 3 months, 16.1% at 6 months, and 17.2% at 12 months, with no responders in the epileptic encephalopathy group. Therapy tolerance was notable, with 70 patients (75.3%) reporting no AEs. Transient AEs occurred in 10 patients (10.7%), and in 13 cases (14.0%), the AEs warranted dose adjustment or discontinuation of BRV. Conclusion: Approximately one-fifth of pediatric patients with drug-resistant epilepsy responded to BRV, with the best response observed in patients with focal seizures. However, the impact on patients with epileptic encephalopathy was limited.
Methods: Our cohort consisted of 93 children (mean age 11.5 +/- 7.5 years) with a wide spectrum of pediatric epilepsy, including epileptic encephalopathy and generalized epilepsy. Of these, 61 (60.4%) were diagnosed with focal epilepsy, 19 (15.8%) with generalized epilepsy, and 16 (15.8%) with combined epilepsy, while 8 patients (7.9%) had an unknown epilepsy type. The cohort included rare epilepsy syndromes: 8 patients with LennoxGastaut syndrome, 3 with Dravet syndrome, and 1 with Rasmussen syndrome. Patients had a history of various antiseizure medications (ASMs) (6.42 +/- 3.15), and on average, were being treated with more than two (2.57 +/- 1.16) drugs at the time of BRV deployment. Results: Retention rates were high, with 80.6% of patients adhering to treatment at 3 months, 66.7% at 6 months, and 45.2% at 12 months. In 29 patients (30.1%), BRV was added in an overnight switch from levetiracetam (LEV), resulting in a reduction of behavioral adverse effects (AEs) in 5 patients (17.2%). The response rate was 25.8% at 3 months, 16.1% at 6 months, and 17.2% at 12 months, with no responders in the epileptic encephalopathy group. Therapy tolerance was notable, with 70 patients (75.3%) reporting no AEs. Transient AEs occurred in 10 patients (10.7%), and in 13 cases (14.0%), the AEs warranted dose adjustment or discontinuation of BRV. Conclusion: Approximately one-fifth of pediatric patients with drug-resistant epilepsy responded to BRV, with the best response observed in patients with focal seizures. However, the impact on patients with epileptic encephalopathy was limited.